Actively Recruiting
Microglia Activation in Asthma
Led by University of Wisconsin, Madison · Updated on 2025-08-26
50
Participants Needed
1
Research Sites
450 weeks
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trail is to learn about how asthma influences brain function. The main questions it aims to answer are: * How airway inflammation in asthma affects the brain; and, * Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 6 visits, participants will: * Complete questionnaires * Complete computer tasks * Undergo allergy skin test * Undergo breathing tests including two whole lung allergen challenges * Give four blood samples * Complete brain imaging scans
CONDITIONS
Official Title
Microglia Activation in Asthma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with no health concerns that might affect the outcome of the study
- Age between 18 and 75 years
- Physician diagnosis of asthma for at least six months prior to screening
- Mild asthma well controlled with low-intensity treatment
- At least 20% decrease in forced expiratory volume (FEV1) after inhaled allergen challenge
- FEV1 of 70% predicted or higher at baseline
- Positive immediate skin test for allergies to cat hair, house dust mite, or ragweed
- Ability to tolerate a simulated MRI brain scan
- Capable and willing to give informed consent and cooperate with study procedures
- High-affinity TSPO-binding genotype; mixed binding affinity may be included at investigator's discretion
You will not qualify if you...
- Current smoker or smoking history exceeding 5 pack years in the last 10 years
- Receiving allergen immunotherapy
- Use of psychotropic medication affecting neurocircuitry function
- Unable to hold medications as required by the study
- Needle phobia or claustrophobia
- Major health problems in the last 6 months such as stroke, myocardial infarction, stent placement, or acute coronary syndrome
- Other major health issues judged by investigators as exclusionary
- Use of biologic medication affecting pathways under study
- Pre-existing chronic infectious disease
- Scheduled use of non-selective beta-blockers before visits
- Current use of beta-1 selective blockers
- Use of investigational drug within 30 days before study entry without appropriate washout
- MRI incompatibility
- History of bipolar disorder, schizophrenia, or schizoaffective disorder
- History of serious head trauma or seizure disorder (unless approved by investigator)
- Unable to comply with study procedures
- Pregnant, breastfeeding, or planning pregnancy during the study
- Corrected vision insufficient to wear contacts or see without glasses
- Medical conditions impacting safety or data integrity
- Never intubated due to asthma and no severe exacerbation requiring emergency or hospitalization in past year
- Participants using ICS for asthma must undergo supervised step-down and maintain well-controlled asthma to continue
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Wisconsin Madison
Madison, Wisconsin, United States, 53703-2637
Actively Recruiting
Research Team
R
Rachel Kaspari
CONTACT
D
Danika Klaus
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here